C-Ray Therapeutics
Website to be confirmed.
About C-Ray Therapeutics
C-Ray Therapeutics is a Radiopharma Developer company; the kind of vendor BD teams should have a 15-minute conversation with at SNMMI.
Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.
What we're seeing
- Endpoints News · 2026-04-01C Ray Therapeutics signs supply agreement to support late-stage trialsThe work builds on more than a decade of radiochemistry collaboration.
- Reuters Health · 2026-07-22C Ray Therapeutics appoints new Chief Medical Officer ahead of pivotal trialDetails remain limited but analysts read the move as a positioning play ahead of pivotal data.
- BioPharma Reporter · 2026-10-15C Ray Therapeutics announces Phase II readout for lead theranostic candidateIndustry observers expect more activity of this kind in the run-up to SNMMI 2026.
- FierceBiotech · 2026-05-08C Ray Therapeutics expands cyclotron capacity to meet Lu-177 demandIndustry observers expect more activity of this kind in the run-up to SNMMI 2026.
Mocked while we wire the Exa integration. Headlines are illustrative.
What we expect to see at the booth
Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.
A short Bracken POV will go here, drawing on our experience across this part of the radiopharma value chain. Specific commentary to be filled in by the team.
Editorial shown for exhibitors in Bracken's wheelhouse: radiopharma developers, isotope supply, CDMO/CMO, cyclotron, and imaging equipment.
Companies you may also want to visit.
Actinium Pharmaceuticals
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on Actinium Pharmaceuticals.
View profile →AtomVie Global Radiopharma Inc.
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on AtomVie Global Radiopharma Inc..
View profile →Bayer Oncology
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on Bayer Oncology.
View profile →